Background: Diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) mismatch was suggested to identify stroke patients with unknown time of symptom onset likely to be within the time window for thrombolysis.
Introduction
Information on the time of symptom onset plays a critical role in acute stroke treatment. Intravenous thrombolysis is approved for treatment within 4.5 h of symptom onset, and for mechanical thrombectomy unequivocal evidence is also only available for treatment within the first 6 h. 1 In about 20% of acute stroke patients however, information on time of symptom onset is not available, e.g. because of patients waking up with stroke symptoms. 2 Stroke MRI with diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR) imaging has been suggested as biomarker of ischemic lesion age. 3 The DWI-FLAIR mismatch, i.e. an acute ischemic lesion visible on DWI without corresponding parenchymal hyperintensity on FLAIR, was demonstrated to have a high positive predictive value in identifying patients within 4.5 h of symptom onset in a multicenter study 4 as well as in several single center studies from different groups. [5] [6] [7] Case series using DWI-FLAIR mismatch to guide intravenous thrombolysis or mechanical thrombectomy in unknown unset stroke patients have previously been published. 8, 9 Using DWI-FLAIR mismatch as surrogate marker of lesion age relies on the assumption that time from symptom onset is the only relevant clinical factor influencing parenchymal hyperintensity on FLAIR and thus the presence or absence of DWI-FLAIR mismatch. There is, however, hardly any data on potential clinical confounders of DWI-FLAIR mismatch in patients with unknown time of symptom onset. Thus, we aimed to identify possible clinical factors of influence on DWI-FLAIR mismatch by comparing clinical characteristics between patients with and without DWI-FLAIR mismatch in a large sample of patients with stroke of unknown onset.
Methods

Study population
We analyzed baseline data from the ongoing WAKE-UP trial (Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial; Clinicaltrials.gov identifier NCT01525290; EudraCT No.: 2011-005906-32). 10 In WAKE-UP MRI including DWI and FLAIR is used for screening stroke patients with unknown time of symptom onset, and patients presenting with DWI-FLAIR mismatch are randomized to treatment with intravenous thrombolysis or placebo. For this analysis we included baseline data of patients enrolled since the start of the trial on 22 September 2011 until 1 April 2016 meeting the following criteria: (1) information on symptom recognition and demographic characteristics available, (2) acute ischemic lesion visible on DWI indicating acute cerebral ischemia, (3) judgment of DWI-FLAIR mismatch available, and (4) no signs of intracerebral hemorrhage on MRI.
DWI-FLAIR mismatch judgment
DWI-FLAIR mismatch was judged by trial investigators according to image analysis standards outlined in the trial protocol and in additional training material. DWI-FLAIR mismatch is defined as the absence of a marked parenchymal hyperintensity in FLAIR in the region of a clearly visible acute DWI lesion, while subtle FLAIR hyperintensities are disregarded. 10 An imaging handbook provides detailed documentation International Journal of Stroke, 13 (1) of the imaging criteria and numerous example cases of the application of the imaging criteria in the trial (see Figure 1 for examples). All investigators judging brain images in WAKE-UP have completed a software-based image analysis training and passed a certification exam.
Data analysis
In order to identify clinical characteristics associated with the presence of DWI-FLAIR mismatch, univariate analysis was performed comparing patients with and without DWI-FLAIR mismatch regarding the following clinical characteristics: age, sex, time between last seen normal and symptom recognition, delay between symptom recognition and hospital arrival, reason for unknown time of symptom onset, neurological deficit on admission assessed by the National Institutes of Health Stroke Scale (NIHSS), medical history and vascular risk factors, current medication, presence of clinical exclusion criteria for thrombolysis. Fisher's exact test or the Chi-square test was used for categorical variables, and nonparametric KruskalWallis test was used for continuous variables. P < 0.05 was considered significant in exploratory analysis without correction for multiple tests. Additionally, we performed a multivariate analysis using logistic regression model to predict the odd of DWI-FLAIR mismatch including all covariates with a p-value 0.15 in univariate analysis. Finally, only parameters with p < 0.05 were retained. SAS software, version 9Á3 (SAS Institute Inc., Cary, NC) was used for all analyses.
Results
Overall, 699 patients met the inclusion criteria. Of those 418 (59.8%) presented with DWI-FLAIR mismatch and 281 (40.2%) had no DWI-FLAIR mismatch. Results of group comparison are shown in Table 1 . Patients with DWI-FLAIR mismatch had a shorter delay between last seen well and symptom recognition (median 7.5 versus 8.0 h, p ¼ 0.0030). A history of atrial fibrillation was more frequent in patients with a DWI-FLAIR mismatch (10.6% versus 4.9%, p ¼ 0.0098). In multivariate analysis, both shorter delay between last seen well and symptom recognition with odds ratio (OR) 0.94 (95% confidence interval 0.91-0.98) and history of AF with OR 2.36 (1.11-5.02) were retained as significant predictors of DWI-FLAIR mismatch (see Table 1 ). In addition, delay between symptom recognition and hospital arrival remained a significant predictor with OR 0.74 (0.62-0.90). All other characteristics were comparable between groups. International Journal of Stroke, 13(1) International Journal of Stroke, 13(1)
Discussion
In this sample of acute stroke patients with unknown time of symptom onset, patients with DWI-FLAIR mismatch indicating symptom onset within 4.5 h were comparable to patients with no DWI-FLAIR mismatch with regards to the vast majority of clinical characteristics. There were no differences in age or severity of neurological symptoms reflected by the NIHSS score. There were also no differences concerning the majority of vascular risk factors, current medication, or the reason why symptom onset was not known. Two parameters differed between groups: the delay between last seen well and symptom recognition was shorter, and history of atrial fibrillation was more frequent in patients with DWI-FLAIR mismatch. This is the first analysis of clinical characteristics in a larger group of stroke patients with unknown time of symptom onset assumed to qualify for reperfusion treatment based on DWI-FLAIR mismatch, and the results confirm the assumption that DWI-FLAIR mismatch as surrogate marker of lesion age is not strongly influenced by clinical characteristics of patients. This is in line with previous studies of DWI-FLAIR mismatch in patients with known symptom onset. In a large multicenter study, patients with DWI-FLAIR mismatch were older but otherwise comparable to patients without a DWI-FLAIR mismatch. 4 This, however, was discussed as a potential confounding effect of leukoaraiosis being more frequent with higher age and interacting with the visibility of acute ischemic lesions on FLAIR in the elderly. In WAKE-UP, severe leukoaraiosis interacting with the judgment of DWI-FLAIR mismatch is considered an exclusion criterion, which may obscure the indirect effect of age observed previously.
With regards to the observed differences between the groups, findings have to be interpreted with caution as they only apply to patients eligible for this analysis which excluded patients with poor quality of MRI or severe leukoaraiosis precluding proper judgment of DWI-FLAIR mismatch. However, the association of DWI-FLAIR mismatch with shorter delays between last seen well and symptom recognition and between symptom recognition and hospital arrival appears biologically plausible considering the visibility of acute ischemic lesions on FLAIR as a function of time. In all previous studies of DWI-FLAIR mismatch in stroke patients with known onset, shorter time from symptom onset was the strongest predictor of DWI-FLAIR mismatch.
3-7 Although we do not know the time of stroke onset in our patients, it may be reasonable to assume that a longer delay between last seen normal and symptom recognition may to a certain extent correlate with a longer delay between stroke onset and symptom recognition.
The higher rate of atrial fibrillation in patients with DWI-FLAIR mismatch is less easily explained and may simply be due to chance. On the other hand, a circadian variation of atrial fibrillation with peak incidence in the morning hours 11 is known, and there are observations of a higher frequency of atrial fibrillation in wake-up stroke. 12, 13 This might provide an explanation for a higher frequency of atrial fibrillation in those patients from our sample with stroke onset in the morning hours shortly before symptom recognition and thus more likely to show DWI-FLAIR mismatch. On the other hand, rates of atrial fibrillation were comparable between patients with wake-up stroke and those with unwitnessed daytime-onset stroke (8.5% versus 7.0%, p ¼ 0.16 Fisher's exact test).
Previous case series have reported on the rates of DWI-FLAIR mismatch in smaller samples with stroke of unclear onset as compared to patients with stroke of known onset, but they did not report on clinical characteristics of patients with DWI-FLAIR mismatch as compared to those without. 14, 15 The proportion of patients with DWI-FLAIR mismatch in our population was slightly higher than in these two previous studies (59.8% as compared to 43.7 and 50.0%), which may result from the fact that in within the context of WAKE-UP being a thrombolysis trial MRI may have been performed more rapidly, and that patients being clearly beyond the time window for thrombolysis, e.g. because of admission to hospital >4.5 h of symptom recognition, were a priori excluded. The decreasing rate of DWI-FLAIR mismatch with time passing appears to parallel decreasing proportions of patients with penumbral pattern with time from stroke onset. 16 Although by concept DWI-FLAIR mismatch and penumbral imaging, e.g. perfusion-diffusion mismatch, address a different pathophysiological phenomenon, i.e. lesion age on the one hand and metabolic tissue status on the other hand, both imaging parameters appear to show a certain association independent from time of stroke onset. 17, 18 Future analyses of the subgroup of patients with perfusion MRI available in the WAKE-UP trial may further improve the understanding of this association. To conclude, the MRI pattern of DWI-FLAIR mismatch was not associated with clinical characteristics except for a longer delay and more frequent atrial fibrillation in the first 699 patients from our trial of intravenous thrombolysis in stroke with unknown symptom onset. Thus, DWI-FLAIR mismatch as indicator of stroke onset of less than 4.5 h does not seem to be confounded by clinical characteristics of stroke patients beyond time from symptom onset and appears well suited as a surrogate marker of lesion age in patients with unknown time International Journal of Stroke, 13 (1) of symptom onset. The question of efficacy and safety of intravenous thrombolysis in unknown symptom onset stroke patients with DWI-FLAIR mismatch will be answered in the final analysis of the WAKE-UP trial.
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